$ECOR 'in review stuff [LOS ANGELES (KABC) -- Hospitalization rates for COVID-19 patients are at an all-time high. And since COVID-19 is a respiratory virus, many people in the hospital find themselves struggling to breathe freely.
But now, a device mainly used to treat migraines has just received emergency use authorization by the Food and Drug Administration to help COVID patients breathe a little easier.
"Antivirals, high-dose steroids, oxygen, inhalers, antibiotics, you name it," said Marshall Bedder, who was hospitalized with COVID-19.
Bedder was prescribed it all as doctors treated him for the coronavirus. He had difficulty breathing and his oxygen levels were low.
"When I was admitted, quite hypoxemic, in the seventies, I was worried," Bedder said.
Then this happened. His oxygen levels went from 91 to 95 in a few minutes and he could breathe easier. The reason behind the sudden relief? A device called GammaCore.
So, what is it?
"GammaCore Sapphire CV was recently authorized by the FDA for use in patients with COVID," said Peter Staats, MD. Staats is the chief medical officer at ElectroCore, which makes the device. He's also the chief medical officer of National Spine and Pain Centers, the largest integrated network of pain physicians in the United States.
The hand-held device works by sending electrical stimulation to the vagus nerve, which serves as the body's "command center" and plays a crucial role in relaying signals throughout the body.
After the vagus nerve is stimulated by the GammaCore, it can help open up the lungs, resulting in increased airflow in COVID-19 patients.
GammaCore, which is typically used to treat migraines, is now one of the latest tools in the fight against COVID-19.
"We may be able to alter the course of the disease such that, if you can breathe better, you won't need to go on a mechanical ventilator," Staats explained.
Patients can use this at home on their own, but they need a prescription from a doctor to obtain the device. Bedder got his device while he was in the hospital and he says it has made all the difference.
"Trust me, when you cannot breathe and there's no other options, it's a tremendous thing," Bedder said.
And there may be more benefits, other than the ones that can be seen immediately.
Staats says the stimulation that GammaCore provides to the vagus nerve can also reduce inflammation and possibly ease the long-term effects of COVID-19.
Report a correction or typo
RELATED TOPICS:
health & fitnesscircle of healthcoronaviruscovid 19 pandemic
Copyright © 2021 KABC-TV. All Rights Reserved.
But now, a device mainly used to treat migraines has just received emergency use authorization by the Food and Drug Administration to help COVID patients breathe a little easier.
"Antivirals, high-dose steroids, oxygen, inhalers, antibiotics, you name it," said Marshall Bedder, who was hospitalized with COVID-19.
Bedder was prescribed it all as doctors treated him for the coronavirus. He had difficulty breathing and his oxygen levels were low.
"When I was admitted, quite hypoxemic, in the seventies, I was worried," Bedder said.
Then this happened. His oxygen levels went from 91 to 95 in a few minutes and he could breathe easier. The reason behind the sudden relief? A device called GammaCore.
So, what is it?
"GammaCore Sapphire CV was recently authorized by the FDA for use in patients with COVID," said Peter Staats, MD. Staats is the chief medical officer at ElectroCore, which makes the device. He's also the chief medical officer of National Spine and Pain Centers, the largest integrated network of pain physicians in the United States.
The hand-held device works by sending electrical stimulation to the vagus nerve, which serves as the body's "command center" and plays a crucial role in relaying signals throughout the body.
After the vagus nerve is stimulated by the GammaCore, it can help open up the lungs, resulting in increased airflow in COVID-19 patients.
GammaCore, which is typically used to treat migraines, is now one of the latest tools in the fight against COVID-19.
"We may be able to alter the course of the disease such that, if you can breathe better, you won't need to go on a mechanical ventilator," Staats explained.
Patients can use this at home on their own, but they need a prescription from a doctor to obtain the device. Bedder got his device while he was in the hospital and he says it has made all the difference.
"Trust me, when you cannot breathe and there's no other options, it's a tremendous thing," Bedder said.
And there may be more benefits, other than the ones that can be seen immediately.
Staats says the stimulation that GammaCore provides to the vagus nerve can also reduce inflammation and possibly ease the long-term effects of COVID-19.
Report a correction or typo
RELATED TOPICS:
health & fitnesscircle of healthcoronaviruscovid 19 pandemic
Copyright © 2021 KABC-TV. All Rights Reserved.
Recent ECOR News
- electroCore Product Line Featured in Documentary Underscoring the Expanding Clinical and Commercial Role of Vagus Nerve Stimulation • GlobeNewswire Inc. • 04/23/2026 12:00:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 04/15/2026 08:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/14/2026 08:05:06 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/14/2026 08:01:02 PM
- electroCore to Participate in the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- electroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 08:01:05 PM
- electroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD • GlobeNewswire Inc. • 04/01/2026 12:00:00 PM
- electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 10:01:50 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/19/2026 09:22:57 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/19/2026 08:35:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 08:10:30 PM
- electroCore Announces Full Year 2025 Financial Results and Organizational Changes • GlobeNewswire Inc. • 03/19/2026 08:05:00 PM
- electroCore to Participate at the 38th Annual Roth Conference • GlobeNewswire Inc. • 03/10/2026 12:00:00 PM
- electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026 • GlobeNewswire Inc. • 03/09/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/28/2026 09:30:06 PM
- Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”) • GlobeNewswire Inc. • 01/21/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 09:05:52 PM
- electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million • GlobeNewswire Inc. • 01/20/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2025 09:15:45 PM
- TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen • GlobeNewswire Inc. • 12/02/2025 01:00:00 PM
- electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum • GlobeNewswire Inc. • 11/10/2025 09:05:00 PM
